期刊
TRANSLATIONAL STROKE RESEARCH
卷 -, 期 -, 页码 -出版社
SPRINGER
DOI: 10.1007/s12975-022-01107-3
关键词
Embolic stroke; Thrombolytic reperfusion therapy; Brain infarction; Hemorrhagic transformation
资金
- Lumosa Therapeutics Co. Ltd. (Taipei City, Taiwan)
The study found that LT3001, a novel synthetic small molecule, has thrombolytic and free radical scavenging activities and may serve as an alternative thrombolytic for stroke treatment. Results showed that LT3001 administered at 1.5 hours after stroke had neuroprotective effects, while treatment at 3 hours after stroke yielded better outcomes in terms of reducing infarct size, swelling rate, and hemorrhagic transformation compared to tPA. LT3001 did not interfere with tPA activity and had no significant impact on related serum levels. Therefore, LT3001 shows promise as a novel therapy for thrombotic ischemic stroke.
LT3001 is a novel synthetic small molecule with thrombolytic and free radical scavenging activities. In this study, we tested the effects of LT3001 as a potential alternative thrombolytic in focal embolic ischemic stroke rat model. Stroked rats received intravenous injection of 10 mg/kg LT3001 or tPA at 1.5, 3, or 4.5 h after stroke, respectively, and the outcomes were measured at different time points after stroke by performing multi-parametric MRI, 2,3,5-triphenyltetrazolium chloride (TTC) staining, and modified neurological severity score. Lastly, we assessed the effect of LT3001 on the tPA activity in vitro, the international normalized ratio (INR), and the serum levels of active tPA and plasminogen activator inhibitor-1 (PAI-1). LT3001 treated at 1.5 h after stroke is neuroprotective by reducing the CBF lesion size and lowering diffusion and T2 lesion size measured by MRI, which is consistent with the reduction in TTC-stained infarction. When treated at 3 h after stroke, LT3001 had significantly better therapeutic effects regarding reduction of infarct size, swelling rate, and hemorrhagic transformation compared to tPA. When treated at 4.5 h after stroke, tPA, but not LT3001, significantly increased brain swelling and intracerebral hemorrhagic transformation. Lastly, LT3001 did not interfere with tPA activity in vitro, or significantly alter the INR and serum levels of active tPA and PAI-1 in vivo. Our data suggests that LT3001 is neuroprotective in focal embolic stroke rat model. It might have thrombolytic property, not interfere with tPA/PAI-1 activity, and cause less risk of hemorrhagic transformation compared to the conventional tPA. Taken together, LT3001 might be developed as a novel therapy for treating thrombotic ischemic stroke.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据